...
【24h】

Rate of malignancy in MRI-detected probably benign (BI-RADS 3) lesions

机译:MRI检测出的良性(BI-RADS 3)病变的恶性率

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE. The purpose of this study was to evaluate the malignancy rate in MRI-detected probably benign (BI-RADS 3) lesions in women without a history of breast cancer. MATERIALS AND METHODS. In this study, 1265 patients underwent breast MRI during a 7-year period. One hundred and eight (8.5%) patients with a nonpalpable breast lesion classified as BI-RADS 3 at MRI and with a needle biopsy or adequate follow-up of at least 24 months were included. Statistical analysis included calculation of the negative predictive value with its 95% CI. RESULTS. Of 108 lesions, 107 (99.1%) were correctly assessed as probably benign, resulting in a negative predictive value of 99.1% (95% CI, 94.99-99.98%). Histopathology was requested by the patient or referring physician in 44 patients. Of these, 43 (39.8%) lesions were classified as benign and one (0.9%) as malignant. There were no changes evident in any of the remaining 64 (59.2%) lesions during follow-up (range, 2-9 years). CONCLUSION. In MRI-detected probably benign (BI-RADS 3) lesions, the malignancy rate is low and within the accepted cancer rate for mammographically or sonographically detected BI-RADS 3 lesions. Short-term follow-up MRI at intervals of 6, 12, and 24 months in MRI BI-RADS 3 lesions remains a strong tool with which to detect suspicious lesions. Interval changes in size, morphology, or enhancement are regarded as indicative of malignancy.
机译:目的。这项研究的目的是评估没有乳腺癌史的女性在MRI中检测到的良性(BI-RADS 3)病变的恶性程度。材料和方法。在这项研究中,有7例患者中有1265例接受了MRI检查。包括一百零八(8.5%)MRI上被分类为BI-RADS 3的不可触及的乳腺病变,并经活检或至少24个月的充分随访的患者。统计分析包括计算阴性预测值及其95%CI。结果。在108个病变中,有107个(99.1%)被正确评估为可能是良性的,导致阴性预测值为99.1%(95%CI,94.99-99.98%)。患者或转诊医师对44例患者进行了组织病理学检查。其中,有43个(39.8%)病变被分类为良性,其中一个(0.9%)被分类为恶性。随访期间(2-9年),其余64个(59.2%)病变中无明显变化。结论。在MRI检测到的良性(BI-RADS 3)病变中,恶性率低,并且在乳房X线或超声检查中检测到的BI-RADS 3病变的癌症发生率处于可接受的范围内。在MRI BI-RADS 3病变中每隔6、12和24个月进行一次短期MRI仍然是检测可疑病变的有力工具。大小,形态或增强的间隔改变被认为是恶性肿瘤的指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号